Intratympanically administered steroid for progressive sensorineural hearing loss in Ménière’s disease

Molnár, András; Maihoub, Stefani; Tamás, László; Szirmai, Ágnes

doi:10.1080/00016489.2019.1658898

Cited by 17 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ITS therapy has displayed good efficacy in the treatment of hearing loss in patients with MD 15,16 and sudden sensorineural hearing loss. 17 Studies have been undertaken to clarify the effectiveness of ITS therapy in the management of vertigo attacks.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of intratympanic dexamethasone for the treatment of vertigo attacks in patients with Ménière’s disease compared with betahistine pharmacotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objective This study analyzed the possible effects of intratympanic steroid (ITS) therapy in the symptomatic treatment of vertigo attacks in patients with Ménière’s disease. Methods Thirty-five patients treated with ITS (dexamethasone) plus betahistine (Group A) and 35 patients treated with betahistine alone (Group B) were enrolled in this investigation. Complaints were analyzed using medical records and vertigo diaries. Statistical analysis was conducted using IBM SPSS V24 software. Results Based on the analysis, there were no significant differences in baseline features between the two groups. When the occurrence of vertigo attacks was compared using the Kaplan–Meier method, no significant difference was detected between Groups A and B (odds ratio [OR] = 1.051, 95% confidence interval [CI] = 0.965–1.067; p = 0.972). In addition, no difference in the incidence of vertigo attacks was noted in group A between the periods of treatment with betahistine alone and betahistine plus ITS when the groups were analyzed via logistic regression (OR = 1.07, 95% CI = 0.065–1.467; p = 0.614). Conclusion It can be concluded that the addition of ITS therapy to betahistine did not improve outcomes in patients with Ménière’s disease. Further prospective studies should be conducted to analyze the results in a more detailed manner.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of intratympanic dexamethasone for the treatment of vertigo attacks in patients with Ménière’s disease compared with betahistine pharmacotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gentamycine is an aminoglycoside antibiotic with a well-known ototoxic effect [7], based on the increase in reactive nitrogen and oxygen species in the inner ear, resulting in dysfunction of hair cells [8]. Intratympanic therapies are widely used in the everyday clinical practice because local application allows higher concentrations in the perilymph with lower applied doses without systemic adverse effects [9,10]. Intratympanic gentamycine (ITG) results in complete or incomplete ablation of the vestibular function, differences in the success of the therapy are based on the individuality of peripheral vestibular function and central compensation [11].…”

Section: Introductionmentioning

confidence: 99%

Intratympanic gentamycine for Ménière’s disease: is there a selective vestibulotoxic effect?

Molnár

Maihoub

Gáborján

et al. 2020

Eur Arch Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

The aim of our study is to investigate the effectiveness and safety of the treatment, based on vertigo diaries and pure tone audiograms. Methods The complete medical documentation of 105 definite patients suffering from Ménière's disease was analyzed. In the studied group, nine patients were treated with intratympanic gentamycine. Long-term follow-up of the patients was carried out, using vertigo diaries, medical letters, anamnestic data, and pure tone audiograms. Audiometric results and vertigo complaints before and after treatment were contrasted using IBM SPSS V24 software. Results Based on our analysis, vertigo attacks appeared significantly less often after gentamycine treatment [p < 0.001; Odds ratio 0.003 (95% CI 0.001-0.012)], which confirms the efficacy of the therapy. Pure tone stages before and after the application of gentamycine were contrasted using the Mann-Whitney U test. When comparing the audiometric results of long-term follow-ups by using the logistic regression, a statistically significant difference was observed between the treated and not treated groups [p = 0.001; Odds ratio 0.141 (95% CI 0.064-0.313)], and based on the survivorship curve hearing impairment was more common in the not treated group which also supports our results. Based on the non-parametric test, there was no significant difference (p = 0.84) between the pure-tone stages of the control group and of those treated with gentamycine. Conclusion Our results indicate that intratympanic gentamycine is effective in controlling vertigo attacks, and there is no higher risk for hearing loss than in case of spontaneous progression of the disorder.

show abstract

“…Ménière disease (MD) is a disorder of the inner ear, characterized by episodic rotational vertigo, sensorineural hearing loss, tinnitus, aural pressure, and vegetative symptoms, such as nausea and vomiting. 1 The pathophysiologic entity of the disease is the endolymphatic hydrops of the inner ear. There seem to be multifactorial causes for MD (of anatomic and genetic origin, allergy, viral infection, etc) and the exact etiology can rarely be determined in an individual patient.…”

Section: Introductionmentioning

confidence: 99%

Conservative Treatment Possibilities of Ménière Disease, Involving Vertigo Diaries

et al. 2019

Self Cite

View full text Add to dashboard Cite

Ménière disease is a disorder of the inner ear, characterized by rotational vertigo, hearing loss, tinnitus, and vegetative symptoms. The aim of the present research is to examine the effectiveness of betahistine and piracetam in the reduction of vertigo attacks in Ménière disease. To verify our hypothesis, 105 (31 male and 74 females, mean age [standard deviation], 57.4 [11.05]) adult patients with definite Ménière disease were enrolled in this investigation. Beside the analysis of the hospital records, the subjective complaints of the patients and the completed vertigo diaries were taken into consideration too. The statistical analysis was completed using the IBM SPSS version 24 software. Retrospective analysis, including a 12 years period was conducted. Based on our results, betahistine was successful in the reduction of attacks. Statistically significant decrease was achieved in frequency of dizziness ( P = .000331) and vertigo ( P < .00001) and in the duration of them ( P = .000098), although in the mean power of them was not ( P = .0887). The mean dose in the symptomatic treatment was determined as 87.5 ± 27.2 mg per day; however, there was no connection detected between the dose of the agent and the effectiveness of the symptomatic control. By using dual therapy (betahistine and piracetam), vertigo episodes appeared significantly less often ( P = .027, Odds ratio: 4.9, 95% confidence interval: 1.2-20.2). Finally, it can be concluded that betahistine is effective in Ménière disease, but the daily dose of it should be set up for every patient individually. The advantage of the dual therapy was also confirmed.

show abstract

Intratympanically administered steroid for progressive sensorineural hearing loss in Ménière’s disease

Cited by 17 publications

References 19 publications

Effectiveness of intratympanic dexamethasone for the treatment of vertigo attacks in patients with Ménière’s disease compared with betahistine pharmacotherapy

Effectiveness of intratympanic dexamethasone for the treatment of vertigo attacks in patients with Ménière’s disease compared with betahistine pharmacotherapy

Intratympanic gentamycine for Ménière’s disease: is there a selective vestibulotoxic effect?

Conservative Treatment Possibilities of Ménière Disease, Involving Vertigo Diaries

Contact Info

Product

Resources

About